One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-155068
Copy DOI Journal: Blood |  Publication Date: Dec 4, 2021 |
 Citations: 9 |
Affiliation: University of Chicago, Institut Català d'Oncologia, Fiona Stanley Hospital, University of Amsterdam, Amsterdam University Medical Centers, University Hospital Cologne, The University of Texas MD Anderson Cancer Center, Tennessee Oncology, Sarah Cannon, Hospices Civils de Lyon, Claude Bernard University Lyon 1, St Vincent's Clinic, UNSW Sydney, St Vincent's Hospital Sydney, University of Sydney, IRCCS Humanitas Research Hospital, Humanitas University, Inserm, Nantes Université, University of Kansas Cancer Center, National University Cancer Institute, Singapore, Centre Hospitalier Universitaire de Lille, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Charité - Universitätsmedizin Berlin, Autonomous University of Barcelona, University Hospital of Zurich, Oregon Health & Science University, LMU Klinikum, Ludwig-Maximilians-Universität München, Paracelsus Medical University, Tris Pharma (United States), Oslo University Hospital, Tohoku University Hospital, University Medical Center Utrecht, Vienna General Hospital, Medical University of Vienna, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, University of Melbourne, Queen Mary Hospital, The Ohio State University, Novartis (Switzerland), Kyushu University Hospital, Hôpital Saint-Louis, Assistance Publique – Hôpitaux de Paris, UPMC Hillman Cancer Center, University of Pennsylvania, Mayo ClinicTisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study
Sign-in/Register to access full text options 
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
